Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

BACKGROUND: Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Aβ), was developed for oral treatment for Alzheimer’s disease (AD). The long-term safety and effect of atabecestat on cognitive performance in participants with predementia AD in two phase 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Novak, Gerald, Streffer, Johannes Rolf, Timmers, Maarten, Henley, David, Brashear, H. Robert, Bogert, Jennifer, Russu, Alberto, Janssens, Luc, Tesseur, Ina, Tritsmans, Luc, Van Nueten, Luc, Engelborghs, Sebastiaan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227237/
https://www.ncbi.nlm.nih.gov/pubmed/32410694
http://dx.doi.org/10.1186/s13195-020-00614-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227237/
https://www.ncbi.nlm.nih.gov/pubmed/32410694
http://dx.doi.org/10.1186/s13195-020-00614-5

Ejemplares similares